A phase 1 trial of Ultragenyx’ treatment for hereditary inclusion-body myopathy caused by GNE mutations is taking place in New York and California

posted on November 30, 2011 - 2:46pm
Update (Feb. 11, 2013): The phase 2 trial is no longer recruiting participants.

New content is being added every day. Please check back again.